Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Vivos Therapeutics (VVOS) Return on Capital Employed (2021 - 2025)

Vivos Therapeutics (VVOS) has disclosed Return on Capital Employed for 5 consecutive years, with 0.89% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Capital Employed rose 32.0% to 0.89% in Q3 2025 year-over-year; TTM through Sep 2025 was 0.89%, a 32.0% increase, with the full-year FY2024 number at 1.39%, up 211.0% from a year prior.
  • Return on Capital Employed was 0.89% for Q3 2025 at Vivos Therapeutics, up from 1.16% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.14% in Q4 2021 to a low of 5.39% in Q4 2023.
  • A 5-year average of 1.81% and a median of 1.16% in 2025 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: tumbled -328bps in 2023, then surged 431bps in 2024.
  • Vivos Therapeutics' Return on Capital Employed stood at 0.14% in 2021, then crashed by -1799bps to 2.71% in 2022, then tumbled by -99bps to 5.39% in 2023, then surged by 80bps to 1.08% in 2024, then increased by 18bps to 0.89% in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Return on Capital Employed are 0.89% (Q3 2025), 1.16% (Q2 2025), and 1.32% (Q1 2025).